Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582280 | 0.93 | TSHR (0.47) | RECQLESRRGHDAC6HPGDTMEM97 | |
| SCHEMBL582948 | 0.88 | POLB (0.43) | POLBL3MBTL1THRBRECQLTDP1 | |
| SCHEMBL1646774 | 0.84 | GAA (0.47) | KMT2AEPHX2CNR2ALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL16823543 | 0.82 | GAA (0.46) | KMT2AEPHX2CNR2ALDH1A1NPC1 | |
| SCHEMBL581314 | 0.81 | POLB (0.47) | POLBKMT2ACNR2ALDH1A1HPGD | |
| SCHEMBL581979 | 0.81 | TSHR (0.45) | RECQLESRRGHDAC6HPGDCRBN | |
| SCHEMBL2407352 | 0.81 | EPHX2 (0.44) | EPHX2NR1H4 | |
| SCHEMBL28545376 | 0.80 | AR (0.39) | TDP1ESRRGKMT2AMEN1EPHX2 | |
| SCHEMBL10020939 | 0.79 | AR (0.42) | KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL191113 | 0.78 | DGAT1 (0.46) | L3MBTL1KMT2AMEN1EPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126962-B2 | Substituted phenylcarbamoyl alkylamino arene compounds and N,N′-BIS-arylurea compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126962-B2 | Substituted phenylcarbamoyl alkylamino arene compounds and N,N′-BIS-arylurea compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9023869-B2 | Substituted phenylcarbamoyl alkylamino arene compounds and N,N'-BIS-arylurea compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023869-B2 | Substituted phenylcarbamoyl alkylamino arene compounds and N,N'-BIS-arylurea compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150031726-A1 | Substituted Phenylcarbamoyl Alkylamino Arene Compounds and N,N'-BIS-Arylurea Compounds | MEDIVATION TECHNOLOGIES LLC | 2015-01-29 | — | — | US | disclosed |
| US-20150031726-A1 | Substituted Phenylcarbamoyl Alkylamino Arene Compounds and N,N'-BIS-Arylurea Compounds | MEDIVATION TECHNOLOGIES LLC | 2015-01-29 | — | — | US | disclosed |
| US-8710086-B2 | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130079372-A1 | Substituted Phenylcarbamoyl Alkylamino Arene Compounds and N,N'-BIS-Arylurea Compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079372-A1 | Substituted Phenylcarbamoyl Alkylamino Arene Compounds and N,N'-BIS-Arylurea Compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| EP-2485804-A1 | SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINO ARENE COMPOUNDS AND N,N'-BIS-ARYLUREA COMPOUNDS | Medivation Prostate Therapeutics, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120184580-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184580-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184580-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2416657-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS FOR USE THEREOF | Medivation Prostate Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2011044327-A1 | SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINO ARENE COMPOUNDS AND N,N'-BIS-ARYLUREA COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044327-A1 | SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINO ARENE COMPOUNDS AND N,N'-BIS-ARYLUREA COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2010118354-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS FOR USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118354-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS FOR USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184580-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | AR, BRDT, AADAC | POLB 4846/4885L3MBTL1 3362/4885THRB 466/4885 |
| US-20130079372-A1 | Substituted Phenylcarbamoyl Alkylamino Arene Compounds and N,N'-BIS-Arylurea Compounds | AR, NAT1, NCOA1 | POLB 2145/4885L3MBTL1 2735/4885THRB 50/4885 |
| US-20150031726-A1 | Substituted Phenylcarbamoyl Alkylamino Arene Compounds and N,N'-BIS-Arylurea Compounds | AR, NAT1, NCOA1 | POLB 2145/4885L3MBTL1 2735/4885THRB 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.